NASH: A global health problem

Hepatology Research

Volumn 41, Issue 7, 2011, Pages 670-674

  Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cirrhosis; Metabolic syndrome; Non alcoholic fatty liver disease; Prevalence

Indexed keywords

ADOLESCENT; AGE; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRINKING BEHAVIOR; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FATTY LIVER; GENE MUTATION; GENETIC ANALYSIS; HEALTH HAZARD; HEPATITIS; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RACE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIAL ASPECT; UNITED STATES; VIRUS HEPATITIS;

EID: 79959795387     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00824.x     Document Type: Review

References (35)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
3. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
4. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 195-203.
5. Chitturi S, Abeygunasekera S, Farrell GC etal. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
6. Marchesini G, Brizi M, Morselli-Labate AM etal. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
8. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care 2008; 31: 587-9.
9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
10. Einhorn D, Reaven GM, Cobin RH etal. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-52.
11. Tsuruta G, Tanaka N, Hongo M etal. Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. J Gastroenterol 2010; 45: 666-72.
12. Caballeria L, Pera G, Auladell MA etal. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010; 22: 24-32.
13. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531-7.
14. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
15. Saadeh S, Younossi ZM, Remer EM etal. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
16. Cassidy FH, Yokoo T, Aganovic L etal. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics 2009; 29: 231-60.
17. Browning JD, Szczepaniak LS, Dobbins R etal. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
18. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-7.
19. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
20. Marcos A, Fisher RA, Ham JM etal. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000; 69: 2410-5.
21. Patton HM, Yates K, Unalp-Arida A etal. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol 2010; 105: 2093-2102.
22. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004; 8: 549-58, viii-ix.
23. Watanabe T, Murata C, Watanabe Y. Metabolic syndrome from the view point of public health: with special reference to nonalcoholic fatty liver disease. Nippon Koshu Eisei Zasshi 2005; 52: 934-42.
24. Kanaya AM, Wassel CL, Mathur D etal. Prevalence and correlates of diabetes in South Asian Indians in the United States: findings from the metabolic syndrome and atherosclerosis in South Asians living in America study and the multi-ethnic study of atherosclerosis. Metab Syndr Relat Disord 2010; 8: 157-64.
25. Bellentani S, Saccoccio G, Masutti F etal. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
26. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
27. Comparcola D, Alisi A, Nobili V. Hepatitis C virus and nonalcoholic Fatty liver disease: similar risk factors for necroinflammation, fibrosis, and cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 97. author reply 97.
28. Sanyal AJ, Contos MJ, Sterling RK etal. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98: 2064-71.
29. Sterling RK, Contos MJ, Smith PG etal. Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008; 47: 1118-27.
30. He S, McPhaul C, Li JZ etal. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-15.
31. Romeo S, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol 2010; 21: 247-52.
32. Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010; 52: 904-12.
33. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
34. Targher G, Bertolini L, Rodella S etal. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.
35. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-91.